FDAapproval65% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Source: FDA
Why This Matters
Why this matters: provides agency context on approval that may shape timing or evidence expectations for Merck Sharp & Dohme LLC.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Hematology · CLL/SLL
- Sub-indication
- General
Related signal: Phase II Trial of Nemtabrutinib with CAR T-cell Therapy in Relapsed/Refractory CLL/SLL